Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04404075 · ClinicalTrials.gov registry record
Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 11
- Enrollment target
NCT04404075: Completed study, sponsored by University of California, San Francisco.
NCT04404075 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04404075 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
Design and beta-test a research-oriented mobile health app to assess disease activity, quality of life, treatment patterns, adverse medication effects, and lifestyle factors in patients with atopic dermatitis.
Primary Outcome
Patient eczema area and severity index (EASI) will be measured. It is a tool for measuring the amount and severity of eczema a patient has on his or her body, scale is 0-72, 0 means clear and 72 means severe eczema
Interventions
- OTHER SkinTracker Mobile App
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2022-04-25 |
| Est. Completion | 2023-05-12 |
What the finished NCT04404075 record still lists
NCT04404075 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 11 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which SkinTracker Mobile App is the first listed.
NCT04404075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04404075 about?
NCT04404075 is a clinical study titled "Skin Tracker: A Mobile Health App to Monitor Skin Disease Activity and Treatment Use". Design and beta-test a research-oriented mobile health app to assess disease activity, quality of life, treatment patterns, adverse medication effects, and lifestyle factors in patients with atopic dermatitis.
What is the current status of trial NCT04404075?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2022-04-25. Estimated completion is 2023-05-12.
What interventions are being tested in trial NCT04404075?
The interventions under investigation include: SkinTracker Mobile App (OTHER).
Who is sponsoring clinical trial NCT04404075?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI